source
- J&J and AbbVie also considered AtaiBeckley before Lilly’s $2.8 B acquisitionJohnson & Johnson and AbbVie were reported to have evaluated AtaiBeckley as a potential target in the psychedelic market. The companies did not submit an offer before Eli Lilly closed its $2.8 bil…
- Kolon’s cell-based gene therapy misses key endpoints in phase 3 osteoarthritis trialKolon TissueGene reported that its phase 3 study of TG‑C, a cell‑based gene therapy for knee osteoarthritis, failed to meet its co‑primary endpoints. Patients receiving the therapy showed no statis…